Literature DB >> 12637506

Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.

Ngoc Vu-Dac1, Philippe Gervois, Heidi Jakel, Maxime Nowak, Eric Bauge, Helene Dehondt, Bart Staels, Len A Pennacchio, Edward M Rubin, Jamila Fruchart-Najib, Jean-Charles Fruchart.   

Abstract

The recently discovered APOA5 gene has been shown in humans and mice to be important in determining plasma triglyceride levels, a major cardiovascular disease risk factor. apoAV represents the first described apolipoprotein where overexpression lowers triglyceride levels. Since fibrates represent a commonly used therapy for lowering plasma triglycerides in humans, we investigated their ability to modulate APOA5 gene expression and consequently influence plasma triglyceride levels. Human primary hepatocytes treated with Wy 14,643 or fenofibrate displayed a strong induction of APOA5 mRNA. Deletion and mutagenesis analyses of the proximal APOA5 promoter firmly demonstrate the presence of a functional peroxisome proliferator-activated receptor response element. These findings demonstrate that APOA5 is a highly responsive peroxisome proliferator-activated receptor alpha target gene and support its role as a major mediator for how fibrates reduce plasma triglycerides in humans.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637506     DOI: 10.1074/jbc.M212191200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

Review 1.  The genetics of familial combined hyperlipidaemia.

Authors:  Martijn C G J Brouwers; Marleen M J van Greevenbroek; Coen D A Stehouwer; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Nat Rev Endocrinol       Date:  2012-02-14       Impact factor: 43.330

2.  Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.

Authors:  G M Dallinga-Thie; A van Tol; H Hattori; L C van Vark-van der Zee; H Jansen; E J G Sijbrands
Journal:  Diabetologia       Date:  2006-04-28       Impact factor: 10.122

Review 3.  Distinct but complementary contributions of PPAR isotypes to energy homeostasis.

Authors:  Vanessa Dubois; Jérôme Eeckhoute; Philippe Lefebvre; Bart Staels
Journal:  J Clin Invest       Date:  2017-04-03       Impact factor: 14.808

Review 4.  Pleiotropic effects of fibrates.

Authors:  Giulia Chinetti-Gbaguidi; Jean Charles Fruchart; Bart Staels
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

5.  SUMOylation of human peroxisome proliferator-activated receptor alpha inhibits its trans-activity through the recruitment of the nuclear corepressor NCoR.

Authors:  Benoit Pourcet; Inés Pineda-Torra; Bruno Derudas; Bart Staels; Corine Glineur
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

6.  Peroxisome proliferator-activated receptor alpha target genes.

Authors:  Maryam Rakhshandehroo; Bianca Knoch; Michael Müller; Sander Kersten
Journal:  PPAR Res       Date:  2010-09-26       Impact factor: 4.964

7.  The Role of PPARα Activation in Liver and Muscle.

Authors:  Lena Burri; G Hege Thoresen; Rolf K Berge
Journal:  PPAR Res       Date:  2010-08-18       Impact factor: 4.964

8.  Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.

Authors:  Xian-sheng Huang; Shui-ping Zhao; Lin Bai; Min Hu; Wang Zhao; Qian Zhang
Journal:  Br J Pharmacol       Date:  2009-08-19       Impact factor: 8.739

9.  Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

Authors:  D Sanoudou; A Duka; K Drosatos; K C Hayes; V I Zannis
Journal:  Pharmacogenomics J       Date:  2009-12-01       Impact factor: 3.550

10.  Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human.

Authors:  Maryam Rakhshandehroo; Guido Hooiveld; Michael Müller; Sander Kersten
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.